激动性抗DCIR抗体抑制ITAM介导的炎症信号传递,并促进免疫解决
Liang Chen1, Suresh Patil1, Jeffrey Barbon2
1AbbVie, Cambridge Research Center, Cambridge, Massachusetts, USA.
JCI insight
|May 23, 2024
概括
开发针对DC抑制受体 (DCIR) 的激动性抗体有效降低了炎症. 这项研究通过激活DCIR信号,为自身免疫和炎症性疾病提供了一种新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 恒定电阻受体 (DCIR) 是髓状细胞上的C型莱克受体,与自身免疫性疾病易感性有关.
- 缺陷的DCIR功能与类风湿性关节炎,狼和Sjögren综合征有关.
- 通过DCIR媒介抑制炎症的机制在很大程度上是未知的.
研究的目的:
- 阐明DCIR激活减少炎症的机制.
- 开发针对炎症性疾病的DCIR新型治疗策略.
主要方法:
- 开发抗DCIR激进抗体.
- 研究DCIR酸化和含SH2的蛋白质氨酸酸酶-2的招募.
- 使用抗体消耗DCIR+细胞.
- 在人类DCIR敲进小鼠模型中验证实验性腹膜炎和结肠炎.
主要成果:
- 抗DCIR激动性抗体促进DCIR酸化和SHP-2招募,从而减少炎症.
- 对DCIR+细胞的消耗也显示出抗炎作用.
- 在肌炎和结肠炎的小鼠模型中,激动性抗DCIR抗体显示出显著的抗炎性质.
结论:
- 用激动性抗体向DCIR是一种有前途的治疗方法,用于炎症性疾病.
- 了解DCIR激活机制为开发针对自身免疫疾病的变革性治疗开辟了道路.
更多相关视频
相关概念视频
Inflammatory Response
2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126


